A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults With Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Substudy

This study is testing new combinations of medications to treat older or medically unfit adults with a fast-growing blood cancer called acute myeloid leukemia that has a specific genetic marker. Doctors want to see if adding a targeted drug called gilteritinib to standard treatments works better to put the cancer into a deeper remission.

You may be able to join if you are 60 years old or older, or under 60 if your doctor feels milder therapy is best for your health, and you have newly diagnosed acute myeloid leukemia with specific FLT3 genetic mutations. You must not have received previous treatments for this type of leukemia.

Participants will be randomly assigned to receive either the standard two-drug combination or a three-drug combination including gilteritinib. Throughout the study, you will have regular check-ups, and doctors will collect tissue and bone marrow samples using a needle to see how well the treatment is working.

The study is currently active and recruiting patients at medical centers in locations such as Birmingham, Alabama, and Tucson, Arizona. Your care team can help you find the closest participating location.